$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2023 Q3 Form 10-Q Financial Statement

#000117867023000015 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $750.5M $318.8M
YoY Change 183.96% 41.78%
Cost Of Revenue $79.47M $85.37M
YoY Change 117.69% 150.81%
Gross Profit $671.1M $233.4M
YoY Change 194.58% 22.33%
Gross Profit Margin 89.41% 73.22%
Selling, General & Admin $199.2M $214.7M
YoY Change -15.55% 26.3%
% of Gross Profit 29.68% 91.99%
Research & Development $253.2M $248.5M
YoY Change 3.18% 20.81%
% of Gross Profit 37.73% 106.49%
Depreciation & Amortization $13.40M $13.18M
YoY Change 26.42% 30.52%
% of Gross Profit 2.0% 5.65%
Operating Expenses $452.4M $463.2M
YoY Change -6.0% 23.3%
Operating Profit $213.9M -$229.8M
YoY Change -182.88% 19.9%
Interest Expense $30.89M -$37.78M
YoY Change -24.81% -188.65%
% of Operating Profit 14.44%
Other Income/Expense, Net -$63.13M -$6.603M
YoY Change -57.32% -92.04%
Pretax Income $150.7M -$274.2M
YoY Change -137.13% -0.17%
Income Tax $2.988M $1.815M
% Of Pretax Income 1.98%
Net Earnings $147.8M -$276.0M
YoY Change -136.4% -0.5%
Net Earnings / Revenue 19.69% -86.59%
Basic Earnings Per Share $1.18 -$2.21
Diluted Earnings Per Share $1.15 -$2.21
COMMON SHARES
Basic Shares Outstanding 125.0M shares 124.5M shares
Diluted Shares Outstanding 131.3M shares 124.7M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.396B $2.058B
YoY Change 6.85% -1.07%
Cash & Equivalents $1.033B $657.8M
Short-Term Investments $1.363B $1.400B
Other Short-Term Assets $158.0M $145.5M
YoY Change 25.88% 12.08%
Inventory $95.77M $100.5M
Prepaid Expenses
Receivables $325.4M $192.5M
Other Receivables $116.4M $28.13M
Total Short-Term Assets $2.985B $2.524B
YoY Change 10.95% 2.12%
LONG-TERM ASSETS
Property, Plant & Equipment $525.6M $736.3M
YoY Change 2.09% 44.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $75.16M $142.1M
YoY Change 22.41% 83.87%
Total Long-Term Assets $853.6M $878.3M
YoY Change 1.09% 2.28%
TOTAL ASSETS
Total Short-Term Assets $2.985B $2.524B
Total Long-Term Assets $853.6M $878.3M
Total Assets $3.839B $3.402B
YoY Change 8.59% 2.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $73.84M $59.75M
YoY Change 82.0% 13.98%
Accrued Expenses $713.1M $640.6M
YoY Change 39.66% 52.07%
Deferred Revenue $77.14M $54.64M
YoY Change -46.51% -52.19%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $949.8M $788.6M
YoY Change 22.9% 19.91%
LONG-TERM LIABILITIES
Long-Term Debt $1.020B $1.019B
YoY Change 0.38% 50.33%
Other Long-Term Liabilities $280.7M $2.003B
YoY Change 53.41% 1173.38%
Total Long-Term Liabilities $280.7M $3.022B
YoY Change 53.41% 1821.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $949.8M $788.6M
Total Long-Term Liabilities $280.7M $3.022B
Total Liabilities $4.005B $3.811B
YoY Change 11.16% 20.8%
SHAREHOLDERS EQUITY
Retained Earnings -$6.872B -$7.019B
YoY Change 8.01% 17.86%
Common Stock $6.738B $6.648B
YoY Change 6.31% 7.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$165.9M -$408.1M
YoY Change
Total Liabilities & Shareholders Equity $3.839B $3.402B
YoY Change 8.59% 2.16%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $147.8M -$276.0M
YoY Change -136.4% -0.5%
Depreciation, Depletion And Amortization $13.40M $13.18M
YoY Change 26.42% 30.52%
Cash From Operating Activities $359.5M -$58.99M
YoY Change -411.84% -51.97%
INVESTING ACTIVITIES
Capital Expenditures $17.10M $15.92M
YoY Change -203.57% -199.15%
Acquisitions
YoY Change
Other Investing Activities $6.300M $7.206M
YoY Change -98.09% -95.46%
Cash From Investing Activities -$10.80M -$8.713M
YoY Change -103.44% -106.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.10M 53.39M
YoY Change -88.86% 76.0%
NET CHANGE
Cash From Operating Activities 359.5M -58.99M
Cash From Investing Activities -10.80M -8.713M
Cash From Financing Activities 33.10M 53.39M
Net Change In Cash 381.8M -14.31M
YoY Change -22.97% -128.43%
FREE CASH FLOW
Cash From Operating Activities $359.5M -$58.99M
Capital Expenditures $17.10M $15.92M
Free Cash Flow $342.4M -$74.91M
YoY Change -446.65% -29.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.29
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120896000 shares
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41136000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5530000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174101000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-259240000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
38115000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
9984000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
76990000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2044000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-276024000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-408131000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
588203000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28059000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30051000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4806000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-240341000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
401166000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13892000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
8090000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34453000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4159000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-277402000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
176040000 usd
us-gaap Net Income Loss
NetIncomeLoss
-450125000 usd
us-gaap Net Income Loss
NetIncomeLoss
-517743000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
27244000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
19557000 usd
alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
22282000 usd
alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
20458000 usd
alny Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
51647000 usd
alny Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
54704000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
115749000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
59764000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-867000 usd
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-32258000 usd
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
-36686000 usd
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
-45692000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-8252000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
17830000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-16183000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-46095000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1582000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7274000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
29109000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
51159000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
766000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
19407000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-23847000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-21434000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
12866000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12167000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-225461000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-294012000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29810000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
33914000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
812887000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1096275000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
757767000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1134138000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
58475000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
24225000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
58475000 usd
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
32725000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
75000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-84930000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
91765000 usd
us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
8000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
99765000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2046000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-208580000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
868556000 usd
us-gaap Interest Paid Net
InterestPaidNet
17128000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5663000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6518000 usd
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2023, we have five marketed products, including one partnered product, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., Europe and Japan.</span></div>
CY2023Q2 alny Number Of Marketed Products
NumberOfMarketedProducts
5 product
CY2023Q2 alny Number Of Partnered Products
NumberOfPartneredProducts
1 product
CY2023Q2 alny Number Of Commercialized Products
NumberOfCommercializedProducts
4 product
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
10300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div>
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4800000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5300000 usd
CY2023Q2 alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-4500000 usd
alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-10200000 usd
CY2022Q2 alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-3500000 usd
alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-7400000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1387753000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
41000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7411000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1380383000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1420603000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
119000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9589000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1411133000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1372451000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1297890000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
7932000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
113243000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1380383000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1411133000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
17449000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
22315000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
116661000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
113783000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
28505000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
25606000 usd
CY2023Q2 alny Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
162615000 usd
CY2022Q4 alny Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
161704000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
657800000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
575558000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2176000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
2177000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
659976000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
577735000 usd
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
5472000 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-2102000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7574000 usd
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-79000 usd
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
8886000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8965000 usd
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75802000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30471000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
115749000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59764000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13942000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14669000 shares
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001178670-23-000015-index-headers.html Edgar Link pending
0001178670-23-000015-index.html Edgar Link pending
0001178670-23-000015.txt Edgar Link pending
0001178670-23-000015-xbrl.zip Edgar Link pending
alny-20230630.htm Edgar Link pending
alny-20230630.xsd Edgar Link pending
alny-20230630_g1.jpg Edgar Link pending
alny2023q210-qex311.htm Edgar Link pending
alny2023q210-qex312.htm Edgar Link pending
alny2023q210-qex321.htm Edgar Link pending
alny2023q210-qex322.htm Edgar Link pending
alnylam2023q2exhibit101.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
alny-20230630_cal.xml Edgar Link unprocessable
alny-20230630_def.xml Edgar Link unprocessable
alny-20230630_lab.xml Edgar Link unprocessable
alny-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alny-20230630_htm.xml Edgar Link completed
image_0a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending